News

The company’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. According to the company, this development allows the generation of a

In the trial, eribulin showed a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, the primary endpoint of the study. The company said that

The drug is also indicated to treat pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Owned by Actavis, Avycaz is a combination of a

Teva’s CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release hydrocodone designed to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative

The approval was on based data from the EDITION clinical trial program, which included a series of international Phase III trials evaluating the efficacy and safety of Toujeo

The three-year deal will see both companies jointly develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR?). According to AstraZeneca, RORy helps to convert a population of

Farydak is the first histone deacetylase (HDAC) inhibitor approved in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication, to treat patients who received at

The trial evaluated the efficacy, safety, tolerability as well as compared two active arms of different doses of TEV-48125, administered as a subcutaneous injection, once a month for

The company’s ANDA product is a generic version of Salix Pharmaceuticals’ Uceris, which is a glucocorticosteroid designed for the induction of remission in patients with active, mild to